Skip to main content

Table 4 Assessment of efficacy and safety based on laboratory data (the treatment discontinuation group)

From: A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use

 

Short-term treatment

Long-term treatment

 

Plasma parameter

Mean ± S.D.

N

Mean ± S.D.

N

p-value

TC

188

±

31.2

31

179

±

39.4

16

0.38

TG

117

±

51.1

30

109

±

50.0

17

0.62

HDL-C

61.4

±

22.6

28

59

±

18.5

17

0.71

LDL-C

102

±

19.2

20

96.6

±

26.4

11

0.56

AST

20.7

±

7.15

33

19.6

±

7.29

26

0.57

ALT

17.6

±

9.37

33

15.3

±

7.74

26

0.32

CPK

81.9

±

40.1

30

83.6

±

44.1

19

0.89

γ-GTP

31.7

±

37.4

26

39.1

±

42.9

21

0.53

ALP

237

±

69.3

23

285

±

134

21

0.16

T-Bil

0.76

±

0.48

24

0.57

±

0.25

20

0.10

LDH

190

±

35.1

30

182

±

56.0

22

0.54

BUN

16.6

±

5.46

35

19.3

±

9.33

27

0.19

Scr

0.85

±

0.28

35

0.91

±

0.41

27

0.52

HbA1c

6.32

±

0.95

22

6.15

±

0.4

11

0.47

  1. Total plasma cholesterol, TC; triglyceride, TG; high-density lipoprotein cholesterol, HDL-C; low-density lipoprotein cholesterol, LDL-C; aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; lactate dehydrogenase, LDH; total bilirubin, T-Bil; blood urea nitrogen, BUN; serum creatinine, Scr; hemoglobin A1c, HbA1c; standard deviation, S.D
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us